Dylan Arthur Garber’s three design patents issued this month (D1123836, D1124346, D1124347) add to a highly consolidated international patent family group—one of two separate families associated with Audien. The ownership trail isn’t immediately obvious from the patents themselves; it only becomes clear after following the USPTO Assignment Center records....
✦ Clinical Takeaway ✦
No actionable change — design patent filings have no bearing on clinical practice.
✦ Why It Matters ✦
Tracking OTC hearing aid patent activity signals how budget-focused brands like Audien are building intellectual property portfolios as the OTC market matures.
✦ Key Points ✦
- 01Three design patents (D1123836, D1124346, D1124347) issued April 2026 to Dylan Arthur Garber.
- 02Patents are linked to a consolidated international patent family associated with OTC brand Audien.
- 03Ownership attribution is indirect — the patents are not straightforwardly assigned to Audien in the filings.
- 04Design patents cover the ornamental appearance of ear devices, not underlying hearing technology.
- 05OTC hearing aid brands are increasingly building IP portfolios following the 2022 FDA OTC rule.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
Three ear device design patents issued in April 2026 are linked to the OTC hearing brand Audien via a consolidated international patent family.
unknownpartially supported
